Wall Street 'Reolysin' Value; Oncolytics Soars on Phase III
Stock buyers hardly cared that Oncolytics Biotech Inc.'s early Phase III results with Reolysin, its reovirus variant for head and neck cancer, lacked survival data and slipped on part of its endpoint – the rest was just too good.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter